Coming out of a 2010 reorganization, Canadian firm MethylGene Inc. entered 2011 with a new CEO at the helm and late Thursday disclosed a C$34.5 million (US$35.3 million) financing round to boost work on its programs in cancer and fungal infections.
Ahead of this week's PDUFA date for ipilimumab in second-line metastatic melanoma, the drug hit its endpoint in the first-line setting, as Bristol-Myers Squibb Co.'s 2009 buyout of Medarex Inc. for $2.4 billion just keeps looking better and better.
Last week, HIV drug developer Koronis Pharmaceuticals Inc. said it was exploring a range of financing options, including a possible listing on London's AIM exchange, to access adequate funding for mid- and late-stage activities. But one alternative the Seattle-based firm won't be considering is a traditional initial public offering (IPO) on Nasdaq.
Two months after a paper in PLoS One highlighted the potential of Koronis Pharmaceuticals Inc.'s HIV candidate KP-1461, the Seattle-based firm is working on the design of a Phase II study aimed at establishing dose and treatment duration for the drug.
Anti-angiogenic drug aflibercept (VEGF-Trap) failed to improve overall survival in a Phase III trial in non-small-cell lung cancer, news that came as no surprise to analysts who have criticized Regeneron Pharmaceuticals Inc.'s and partner Paris-based Sanofi-Aventis SA's aggressive move into late-stage trials.
Taking advantage of a recent stock bump, multi-focused drug and diagnostic firm OPKO Health Inc. is raising $101.3 million in a public stock sale of 27 million shares priced at $3.75 apiece.
Ziopharm Oncology Inc. inked its first partnership for organic arsenic drug darinaparsin, signing a regional deal with Tokyo-based Solasia Pharma K.K. focused on specific Pan-Asian/Pacific territories.
